What's driving Cancer Biological Therapy Market ; Eminent Players - AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Celgene Corporation, Eisai, ELI Lilly and Company, F. Hoffmann-La Roche, GlaxoSmithKline, Incyte, Merck, Novartis, Otsuka, Pfizer, Sanofi, Sea

Cancer biological therapy market to exceed the 100 billion-dollar mark by 2023, U.S. to be the key growth avenue.
Cancer is becoming a leading cause of death on a global scale, owing to which cancer biological therapy market has witnessed a significant surge over the recent years. According to WHO, over 14 million new cases and 8.2 million cancer related deaths was recorded in 2012. Furthermore, WHO also estimated new cancer cases to raise by 70% over the next two decades. Tobacco consumption is considered as the most prominent risk factor stimulating the cancer occurrence in people.

The growing geriatric population is more prone to cancer as per the statistics documented by ACS. Individuals aged 50 and above accounted for more than 86% of cases in the US. As per the reports, In US, more than 246,660 breast cancer cases and 180,890 prostate cancer cases had been diagnosed in 2016. This has considerably surged the global cancer biological therapy market share which was worth USD 61.3 billion in 2015. As per a report by Global Market Insights, Inc., Cancer Biological Therapy Market is estimated to cross USD 100 billion mark by 2023, by attaining a growth rate of 6% over 2016-2023.

Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/676

Cancer biological therapy uses the body’s immune system to fight cancer or to lessen the side effects. Cancer vaccines & monoclonal antibodies are among the most promising biological approaches toward cancer treatments. The antibody therapy has by far been the most thriving approach for the treatment of solid tumors and hematological malignancies. Over the period of 2016-2023, the bispecific monoclonal antibodies market is projected to grow at an annual rate of 6.5%, thereby fueling cancer biological therapy industry growth. The cancer vaccines market is also projected to grow at an annual rate of 17.2% over 2016-2023.

Japan contributes a major share in the Asia Pacific cancer biological therapy industry, subject to high prevalence of cancer in growing geriatric population base. The region covered more than 40% of overall APAC revenue share in 2015. Furthermore, China is also set to provide huge growth potential for cancer biological therapy market with favorable government policies and investment in R&D to innovate novel treatments. Strong governmental support and beneficial reimbursement policies will attract huge investments by the industry players to advance the manufacturing capabilities.

Make Inquiry about this report @ https://www.gminsights.com/inquiry-before-buying/676

North America cancer biological therapy market is driven by a considerable increase in local and private funds for research and development activities. U.S. was the leading country accounting for more than 80% of North American revenue generation in 2015. Germany cancer biological therapy industry acquired a major revenue chunk of the overall Europe market in 2015. Favorable insurance policies in the region are expected to boost the industry share over the coming years.

Company players are majorly focusing on developing various innovative products with minimal side effects. Prominent companies are targeting on the invention of novel drugs to sustain their market positions. Encouraging governmental initiatives and funding have further created new growth avenues for the industry participants. Some of the key cancer biological therapy industry players include Bristol-Myers Squibb, Eli Lilly, Celgene Corporation, Seattle Genetics, Inc., Amgen Inc., GlaxoSmithKline Plc, Novartis International Ag, F. Hoffmann-La Roche AG, Spectrum Pharmaceuticals, Inc., and Merck & Co., Inc.

Report Content
Chapter 1. Methodology
1.1. Methodology
1.2. Market definitions
1.3. Forecast parameters
1.4. Data sources
1.4.1. Secondary
1.4.1.1. Paid sources
1.4.1.2. Unpaid sources
1.4.2. Primary
Chapter 2. Executive Summary
2.1. Cancer biological therapy industry 3600 synopsis, 2013 - 2024
2.1.1. Business trends
2.1.2. Product trends
2.1.3. Regional trends
Chapter 3. Cancer Biological Therapy Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2013 - 2024
3.3. Industry impact forces
3.3.1. Growth drivers
3.3.1.1. Increasing incidence of cancer worldwide
3.3.1.2. Growing geriatric population
3.3.1.3. Technological advancement in cancer biologics in developed countries
3.3.1.4. Increasing R&D funding coupled with favorable government policies
3.3.2. Industry pitfalls and challenges
3.3.2.1. High cost of treatment
3.3.2.2. Adverse effects of anti-cancer drug therapy
3.4. Growth potential analysis
3.4.1. By product
3.5. Porter’s analysis
3.6. Competitive landscape, 2017
3.6.1. Strategy dashboard
3.7. PESTEL analysis

Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Blog : http://news-researchers.com/

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

This release was published on openPR.